Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an announcement.
On December 19, 2025, OKYO Pharma marked its progress in developing treatments for neuropathic corneal pain by having Executive Chairman and Founder Gabriele Cerrone and the management team ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York. The ceremony highlighted the company’s clinical advances with its lead candidate urcosimod, which recently delivered positive Phase 2 results in NCP, demonstrating favorable corneal nerve outcomes and pain reduction in patients facing a debilitating condition without approved therapies. OKYO is leveraging this momentum as it prepares a larger, multicenter Phase 2 trial of urcosimod in NCP, planned to begin in the first quarter of 2026, underscoring its bid to strengthen its position in ocular pain therapeutics and signaling potential long-term implications for patients and investors if subsequent trials confirm these early efficacy signals.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and other ocular diseases. Listed on the Nasdaq Capital Market, the company’s lead drug candidate is urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor, which has shown anti-inflammatory and pain-reducing activity in preclinical models and positive Phase 2 results in both dry eye disease and NCP, where no FDA-approved treatments currently exist.
Average Trading Volume: 154,692
Technical Sentiment Signal: Hold
Current Market Cap: $68.83M
For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.